Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iradimed (IRMD) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $0.44.

  • Iradimed's EPS (Basic) rose 1000.0% to $0.44 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.67, marking a year-over-year increase of 1283.78%. This contributed to the annual value of $1.46 for FY2024, which is 757.26% up from last year.
  • Per Iradimed's latest filing, its EPS (Basic) stood at $0.44 for Q3 2025, which was up 1000.0% from $0.45 recorded in Q2 2025.
  • In the past 5 years, Iradimed's EPS (Basic) ranged from a high of $0.45 in Q2 2025 and a low of $0.11 during Q1 2021
  • Its 5-year average for EPS (Basic) is $0.31, with a median of $0.33 in 2023.
  • Over the last 5 years, Iradimed's EPS (Basic) had its largest YoY gain of 54000.0% in 2021, and its largest YoY loss of 2666.67% in 2021.
  • Quarter analysis of 5 years shows Iradimed's EPS (Basic) stood at $0.32 in 2021, then fell by 9.37% to $0.29 in 2022, then grew by 24.14% to $0.36 in 2023, then fell by 2.46% to $0.35 in 2024, then grew by 25.3% to $0.44 in 2025.
  • Its EPS (Basic) was $0.44 in Q3 2025, compared to $0.45 in Q2 2025 and $0.37 in Q1 2025.